Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shenyang Xingqi Pharmaceutical (300573 CH)
Watchlist
14
Analysis
Health Care
•
China
Shenyang Xingqi Pharmaceutical Co., Ltd. is a pharmaceutical company. The Company researches, produces, and distributes ophthalmic medicines including anti-bacterial products, allergy medicines, cataract preventions, and glaucoma treatments.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Shenyang Xingqi Pharmaceutical
•
08 May 2024 06:10
ChiNext/ChiNext50 Index Rebalance Preview: Outperformance Continues
There could be 7 changes for the Chinext and 5 changes for the Chinext50. There are 6 overlapping stocks and those have the largest flows. The...
Brian Freitas
Follow
218 Views
Share
bullish
•
Shenyang Xingqi Pharmaceutical
•
18 Apr 2024 05:50
ChiNext/ChiNext50 Index Rebalance Preview: Plenty of Overlap Between the Indices
Nearing the end of the review period, we forecast 8 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index in June...
Brian Freitas
Follow
448 Views
Share
bullish
•
Shenyang Xingqi Pharmaceutical
•
17 Mar 2024 19:50
China Healthcare Weekly (Mar.15)- New Policy of Innovative Drug, TCM Formula Granules, Xingqi Pharma
New policy of innovative drug is a big deal. We've reasons to start being optimistic.The market pattern of TCM formula granules will face...
Xinyao (Criss) Wang
Follow
325 Views
Share
bullish
•
CSPC Innovation Pharmaceutical-A
•
06 May 2024 20:23
Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Bull-Bear Hot Streak Continues; Some Surprises
The Bullish Names have outperformed the Bearish Names by +17.7% since I published my last ChiNext insight on 10th April 2024.
Janaghan Jeyakumar, CFA
Follow
194 Views
Share
bullish
•
CSPC Innovation Pharmaceutical-A
•
10 Apr 2024 17:39
Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Bullish Names Outperform Bearish Names Again
The Bullish Names have outperformed the Bearish Names in successive insights. There were 5.75% and 4.18% outperformances in the periods between Mid...
Janaghan Jeyakumar, CFA
Follow
402 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.31.2
x